Publications by authors named "A B Karnad"
Article Synopsis
- Diffuse large B-cell lymphoma (DLBCL) is a serious type of cancer where the current treatment, R-CHOP, cures only about 60% of patients, prompting the need for improved therapies.
- Researchers investigated the combination of the FDA-approved PDE4 inhibitor roflumilast with R-CHOP in high-risk, treatment-naïve DLBCL patients, which showed safety and encouraging outcomes, with 70% of patients alive and disease-free at 44 months.
- Initial results indicate that roflumilast could enhance cancer treatment by inhibiting certain cancer-related signals and may be especially effective for specific high-risk genetic subtypes of DLBCL, suggesting further testing is needed.
A charge-current-induced shift in the spin-locked Fermi surface leads to a non-equilibrium spin density at a Rashba interface, commonly known as the Rashba-Edelstein effect. Since this is an intrinsically interfacial property, direct detection of the spin moment is difficult. Here we demonstrate that a planar Josephson Junction, realized by placing two closely spaced superconducting electrodes over a Rashba interface, allows for a direct detection of the spin moment as an additional phase in the junction.
View Article and Find Full Text PDFPurpose: To understand the spectrum and volume of classical hematology (CH) referrals to hematology clinics at a National Cancer Institute (NCI)-designated cancer center (CC) to plan for the delivery of effective and equitable care for this population.
Methods: One referral office at the Academic CC located in Bexar County, TX, handles all adult hematology referrals. From October 1, 2021, to September 30, 2022, all nonmalignant hematology (MH) referrals were triaged daily to define the category of CH problem.
Chemoresistance in pancreatic cancer cells may be caused by the expansion of inherently resistant cancer cells or by the adaptive plasticity of initially sensitive cancer cells. We investigated how CD44 isoforms switching contributed to gemcitabine resistance. Treating CD44 null/low single-cell clones with increasing amounts of gemcitabine caused an increase in expression of CD44 and development of gemcitabine resistant (GR) cells.
View Article and Find Full Text PDFBackground: Novel approaches are required to improve outcomes in relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma. We aimed to evaluate camidanlumab tesirine, an anti-CD25 antibody-drug conjugate, in this patient population.
Methods: This was a phase 1, dose-escalation (part 1), dose-expansion (part 2), multicentre trial done in 12 hospital sites (seven in the USA and five in the UK).